• Login
    View Item 
    •   Home
    • UA Faculty Research
    • UA Faculty Publications
    • View Item
    •   Home
    • UA Faculty Research
    • UA Faculty Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UA Campus RepositoryCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournalThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournal

    My Account

    LoginRegister

    About

    AboutUA Faculty PublicationsUA DissertationsUA Master's ThesesUA Honors ThesesUA PressUA YearbooksUA CatalogsUA Libraries

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    JPR-132595-use-of-immediate-re ...
    Size:
    341.4Kb
    Format:
    PDF
    Description:
    FInal Published Version
    Download
    Author
    Silverman, Sanford
    Raffa, Robert B
    Cataldo, Marc
    Kwarcinski, Monica
    Ripa, Steven R.
    Affiliation
    Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol
    Issue Date
    2017-05
    Keywords
    buprenorphine transdermal system
    ER opioids
    chronic low-back pain
    chronic noncancer pain
    Butrans
    supplemental analgesia
    breakthrough pain
    
    Metadata
    Show full item record
    Publisher
    DOVE MEDICAL PRESS LTD
    Citation
    Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system 2017, Volume 10:1255 Journal of Pain Research
    Journal
    Journal of Pain Research
    Rights
    © 2017 Silverman et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.
    Collection Information
    This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
    Abstract
    Background: The buprenorphine transdermal system (BTDS) is approved in the US for the management of chronic pain. Due to its high affinity for mu-opioid receptors with a slow dissociation profile, buprenorphine may potentially displace or prevent the binding of competing mu-opioid-receptor agonists, including immediate-release (IR) opioids, in a dose-dependent manner. Health care professionals may assume that the use of IR opioids for supplemental analgesia during BTDS therapy is not acceptable. Materials and methods: This post hoc analysis evaluated the use of IR opioids as supplemental analgesia during the management of moderate-severe chronic pain with BTDS at 52 US sites (BUP3015S, NCT01125917). Patients were categorized into IR-opioid and no-IR-opioid groups. At each visit of the extension phase, adverse events, concomitant medications, and information from the Brief Pain Inventory (BPI) were recorded. Results: The most common supplemental IR opioids prescribed during BTDS treatment (n=354) were hydrocodone-acetaminophen and oxycodone-acetaminophen. The mean daily dose of IR opioids (morphine equivalents) for supplemental analgesia was 22 mg. At baseline, BPI pain intensity and BPI - interference scores were higher for patients in the IR-opioid group. In both treatment groups, scores improved by week 4, and then were maintained throughout 6 months of the open-label extension trial. The incidence of treatment-emergent adverse events was similar in both groups. Conclusion: Patients who were prescribed IR opioids reported lower scores for BPI pain intensity and pain interference to levels similar to patients receiving BTDS without IR opioids, without increasing the rate or severity of treatment-emergent adverse events. Patients prescribed concomitant use of IR opioids with BTDS had greater treatment persistence. The results of this post hoc analysis provide support for the concomitant use of IR opioids for supplemental analgesia during the management of moderate-severe chronic pain with BTDS.
    Note
    Open Access Journal
    ISSN
    1178-7090
    PubMed ID
    28579823
    DOI
    10.2147/JPR.S132595
    Version
    Final published version
    Sponsors
    Purdue Pharma LP
    Additional Links
    https://www.dovepress.com/use-of-immediate-release-opioids-as-supplemental-analgesia-during-mana-peer-reviewed-article-JPR
    ae974a485f413a2113503eed53cd6c53
    10.2147/JPR.S132595
    Scopus Count
    Collections
    UA Faculty Publications

    entitlement

    Related articles

    • Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    • Authors: Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C
    • Issue date: 2011 Dec
    • Buprenorphine transdermal system utilization.
    • Authors: Wallace L, Kadakia A
    • Issue date: 2017 Jan
    • Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
    • Authors: Yarlas A, Miller K, Wen W, Lynch SY, Munera C, Pergolizzi JV Jr, Raffa R, Ripa SR
    • Issue date: 2015 Jan
    • Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    • Authors: Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR
    • Issue date: 2007 Oct
    • Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    • Authors: Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P
    • Issue date: 2008 Jul-Aug
    The University of Arizona Libraries | 1510 E. University Blvd. | Tucson, AZ 85721-0055
    Tel 520-621-6442 | repository@u.library.arizona.edu
    DSpace software copyright © 2002-2017  DuraSpace
    Quick Guide | Contact Us | Send Feedback
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.